EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Novel hydrazone compounds with broad-spectrum antiplasmodial activity and synergistic interactions with antimalarial drugs

Angélica M Rosado-Quiñones, Emilee E Colón-Lorenzo, Zarna Rajeshkumar Pala, Jürgen Bosch, Karl Kudyba, Heather Kudyba, Susan E Leed, Norma Roncal, Abel Baerga-Ortiz, Abiel Roche-Lima, Yamil Gerena, David A Fidock und 3 weitere

Antimicrobial Agents and Chemotherapy · 2024

DOI: 10.1128/aac.01643-23 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2024. Verfasst von Angélica M Rosado-Quiñones und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology and Medical Zoology, University of Puerto Rico School of Medicine, San Juan, Puerto Rico. Hauptthemen laut MEDLINE: Antimalarials, Hydrazones, Plasmodium falciparum, Drug Synergism. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 71 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIMHD NIH HHS, HHS | NIH | NIAID | Division of Intramural Research (DIR, NIAID), NIGMS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The development of novel antiplasmodial compounds with broad-spectrum activity against different stages of Plasmodium parasites is crucial to prevent malaria disease and parasite transmission. This study evaluated the antiplasmodial activity of seven novel hydrazone compounds (referred to as CB compounds: CB-27, CB-41, CB-50, CB-53, CB-58, CB-59, and CB-61) against multiple stages of Plasmodium parasites. All CB compounds inhibited blood stage proliferation of drug-resistant or sensitive strains of Plasmodium falciparum in the low micromolar to nanomolar range. Interestingly, CB-41 exhibited prophylactic activity against hypnozoites and liver schizonts in Plasmodium cynomolgi , a primate model for Plasmodium vivax . Four CB compounds (CB-27, CB-41, CB-53, and CB-61) inhibited P. falciparum oocyst formation in mosquitoes , and five CB compounds (CB-27, CB-41, CB-53, CB-58, and CB-61) hindered the in vitro development of Plasmodium berghei ookinetes. The CB compounds did not inhibit the activation of P. berghei female and male gametocytes in vitro . Isobologram assays demonstrated synergistic interactions between CB-61 and the FDA-approved antimalarial drugs, clindamycin and halofantrine. Testing of six CB compounds showed no inhibition of Plasmodium glutathione S-transferase as a putative target and no cytotoxicity in HepG2 liver cells. CB compounds are promising candidates for further development as antimalarial drugs against multidrug-resistant parasites, which could also prevent malaria transmission.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AntimalarialsHydrazonesPlasmodium falciparumDrug SynergismPlasmodium bergheiAnimalsHumansMiceFemalePlasmodium cynomolgiHep G2 CellsPlasmodium vivaxMalariaMale

Stichwörter der Autor:innen

Plasmodium bergheiPlasmodium falciparumdrug combinationsmalariamultistage activity

Substanzen

AntimalarialsHydrazones

Autor:innen und Institutionen

  • Department of Microbiology and Medical Zoology, University of Puerto Rico School of Medicine, San Juan, Puerto Rico.
  • Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, Maryland, USA.
  • Center for Global Health and Diseases, Case Western Reserve University, Cleveland, Ohio, USA.
  • InterRayBio, LLC, Cleveland, Ohio, USA.
  • Department of Drug Discovery, Experimental Therapeutics Branch, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA.
  • Department of Biochemistry, University of Puerto Rico School of Medicine, San Juan, Puerto Rico.

ORCID-Profile: Joel Vega-Rodríguez, Adelfa E Serrano

Förderung

  • NIMHD NIH HHS
  • HHS | NIH | NIAID | Division of Intramural Research (DIR, NIAID)
  • NIGMS NIH HHS
  • HHS | NIH | National Institute on Minority Health and Health Disparities (NIMHD)
  • HHS | NIH | National Institute of General Medical Sciences (NIGMS)

Zitieren

APA

Rosado-Quiñones, A. M., Colón-Lorenzo, E. E., Pala, Z. R., Bosch, J., Kudyba, K., Kudyba, H., Leed, S. E., Roncal, N., Baerga-Ortiz, A., Roche-Lima, A., Gerena, Y., Fidock, D. A., Roth, A., Vega-Rodríguez, J., & Serrano, A. E. (2024). Novel hydrazone compounds with broad-spectrum antiplasmodial activity and synergistic interactions with antimalarial drugs. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.01643-23

Vancouver

Rosado-Quiñones AM, Colón-Lorenzo EE, Pala ZR, Bosch J, Kudyba K, Kudyba H, et al. Novel hydrazone compounds with broad-spectrum antiplasmodial activity and synergistic interactions with antimalarial drugs. Antimicrobial Agents and Chemotherapy. 2024. doi:10.1128/aac.01643-23

BibTeX
@article{RosadoQuiones2024,
  author = {Rosado-Quiñones, Angélica M and Colón-Lorenzo, Emilee E and Pala, Zarna Rajeshkumar and Bosch, Jürgen and Kudyba, Karl and Kudyba, Heather and Leed, Susan E and Roncal, Norma and Baerga-Ortiz, Abel and Roche-Lima, Abiel and Gerena, Yamil and Fidock, David A and Roth, Alison and Vega-Rodríguez, Joel and Serrano, Adelfa E},
  title = {Novel hydrazone compounds with broad-spectrum antiplasmodial activity and synergistic interactions with antimalarial drugs},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2024},
  doi = {10.1128/aac.01643-23}
}
Kostenlos starten →